Sodium/Glucose Cotransporter 2 clinical trials
How each study uses Sodium/Glucose Cotransporter 2 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Sodium/Glucose Cotransporter 2 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Other names
- SGLT2
- 1
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Aswan University (1) · University of Aberdeen (1) · Prof. Dr. med. Ingo Eitel (1)
Studies
Open first, then newest update. How each study uses Sodium/Glucose Cotransporter 2 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related CardiotoxicityRecruitingNot applicableUniversity of AberdeenNCT07070765Written as Sodium-glucose transport-2 (SGLT-2) inhibitorsHow we know
- SGLT2 Inhibition for Cardiovascular Endpoint Reduction in HypertensionRecruitingPhase 3Prof. Dr. med. Ingo EitelNCT06804161Written as SGLT2How we know
- Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial RemodelingCompletedNot applicableAswan UniversityNCT05993897Written as Sodium Glucose Co-transporter 2 (SGLT2) InhibitorHow we know
Given beside what is tested · 1 — Sodium/Glucose Cotransporter 2 is usual care or a partner of the new treatment
- A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in TurkeyCompletedPhase 4SanofiNCT02954692Written as Sodium-glucose transport-2 (SGLT-2) inhibitorsHow we know
As the comparator · 2 — what is tested is compared with Sodium/Glucose Cotransporter 2
- Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 DiabetesRecruitingEarly Phase 1Vanderbilt University Medical CenterNCT06609356Written as Sodium Glucose Co-transporter 2 (SGLT2) InhibitorHow we know
- Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic RegimenCompletedPhase 4Yonsei UniversityNCT04013581Written as SGLT-2 groupHow we know